Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 7;26(2):444.
doi: 10.3390/ijms26020444.

The Rise of Fentanyl: Molecular Aspects and Forensic Investigations

Affiliations
Review

The Rise of Fentanyl: Molecular Aspects and Forensic Investigations

Cecilia Barletta et al. Int J Mol Sci. .

Abstract

Fentanyl is a synthetic opioid widely used for its potent analgesic effects in chronic pain management and intraoperative anesthesia. However, its high potency, low cost, and accessibility have also made it a significant drug of abuse, contributing to the global opioid epidemic. This review aims to provide an in-depth analysis of fentanyl's medical applications, pharmacokinetics, metabolism, and pharmacogenetics while examining its adverse effects and forensic implications. Special attention is given to its misuse, polydrug interactions, and the challenges in determining the cause of death in fentanyl-related fatalities. Fentanyl misuse has escalated dramatically, driven by its substitution for heroin and its availability through online platforms, including the dark web. Polydrug use, where fentanyl is combined with substances like xylazine, alcohol, benzodiazepines, or cocaine, exacerbates its toxicity and increases the risk of fatal outcomes. Fentanyl undergoes rapid distribution, metabolism by CYP3A4 into inactive metabolites, and renal excretion. Genetic polymorphisms in CYP3A4, OPRM1, and ABCB1 significantly influence individual responses to fentanyl, affecting its efficacy and potential for toxicity. Fentanyl's side effects include respiratory depression, cardiac arrhythmias, gastrointestinal dysfunction, and neurocognitive impairments. Chronic misuse disrupts brain function, contributes to mental health disorders, and poses risks for younger and older populations alike. Fentanyl-related deaths require comprehensive forensic investigations, including judicial inspections, autopsies, and toxicological analyses. Additionally, the co-administration of xylazine presents distinct challenges for the scientific community. Histological and immunohistochemical studies are essential for understanding organ-specific damage, while pharmacogenetic testing can identify individual susceptibilities. The growing prevalence of fentanyl abuse highlights the need for robust forensic protocols, advanced research into its pharmacogenetic variability, and strategies to mitigate its misuse. International collaboration, public education, and harm reduction measures are critical for addressing the fentanyl crisis effectively.

Keywords: abuse; fentanyl; pharmacogenetic; synthetic opioid; toxicology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
This figure provides an overview of the complex and far-reaching adverse effects fentanyl has on various bodily systems. (created with BioRender, https://biorender.com).

References

    1. Stanley T.H. The Fentanyl Story. J. Pain. 2014;15:1215–1226. doi: 10.1016/j.jpain.2014.08.010. - DOI - PubMed
    1. Albores-García D., Cruz S.L. Fentanyl and Other New Psychoactive Synthetic Opioids. Challenges to Prevention and Treatment. Rev. Investig. Clin. 2023;75:93–104. doi: 10.24875/RIC.23000109. - DOI - PubMed
    1. Vardanyan R.S., Hruby V.J. Fentanyl-Related Compounds and Derivatives: Current Status and Future Prospects for Pharmaceutical Applications. Future Med. Chem. 2014;6:385–412. doi: 10.4155/fmc.13.215. - DOI - PMC - PubMed
    1. Comer S.D., Cahill C.M. Fentanyl: Receptor Pharmacology, Abuse Potential, and Implications for Treatment. Neurosci. Biobehav. Rev. 2019;106:49–57. doi: 10.1016/j.neubiorev.2018.12.005. - DOI - PMC - PubMed
    1. Edinoff A.N., Kaplan L.A., Khan S., Petersen M., Sauce E., Causey C.D., Cornett E.M., Imani F., Moghadam O.M., Kaye A.M., et al. Full Opioid Agonists and Tramadol: Pharmacological and Clinical Considerations. Anesth. Pain. Med. 2021;11:e119156. doi: 10.5812/aapm.119156. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources